Bokf, Na Vertex Pharmaceuticals Inc Transaction History

Bokf, Na

$5.65 Billion
Q3 2024

A detailed history of Bokf, Na transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Bokf, Na holds 7,853 shares of VRTX stock, worth $3.54 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

7,853

Previous 8,003 1.87%

Holding current value

$3.54 Million

Previous $3.75 Million 2.64%

% of portfolio

0.06%

Previous 0.07%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$460.0 - $505.78 $69,000 - $75,867	-150 Reduced 1.87%	7,853 $3.65 Million
Q2 2024 Aug 07, 2024	SELL	$392.81 - $485.53 $875,573 - $1.08 Million	-2,229 Reduced 21.78%	8,003 $3.75 Million
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $3.78 Million - $4.14 Million	-9,274 Reduced 47.54%	10,232 $4.28 Million
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $34,300 - $41,068	-100 Reduced 0.51%	19,506 $7.94 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $133,242 - $142,809	394 Added 2.05%	19,606 $6.82 Million
Q2 2023 Aug 21, 2023	SELL	$314.42 - $351.91 $241,788 - $270,618	-769 Reduced 3.85%	19,212 $6.76 Million
Q1 2023 May 11, 2023	SELL	$283.23 - $323.1 $894,157 - $1.02 Million	-3,157 Reduced 13.64%	19,981 $6.3 Million
Q4 2022 Feb 13, 2023	BUY	$285.76 - $321.48 $4.66 Million - $5.24 Million	16,308 Added 238.77%	23,138 $6.68 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $21,358 - $23,831	-78 Reduced 1.13%	6,830 $1.98 Million
Q2 2022 Aug 11, 2022	SELL	$234.96 - $292.55 $1.1 Million - $1.37 Million	-4,668 Reduced 40.32%	6,908 $1.95 Million
Q1 2022 May 13, 2022	SELL	$221.42 - $260.97 $2,657 - $3,131	-12 Reduced 0.1%	11,576 $3.02 Million
Q4 2021 Mar 11, 2022	SELL	$177.01 - $223.45 $255,779 - $322,885	-1,445 Reduced 11.09%	11,588 $2.55 Million
Q3 2021 Nov 10, 2021	SELL	$181.39 - $202.99 $687,830 - $769,738	-3,792 Reduced 22.54%	13,033 $2.36 Million
Q1 2021 Apr 21, 2021	SELL	$207.02 - $241.31 $5.22 Million - $6.08 Million	-25,204 Reduced 59.97%	16,825 $3.62 Million
Q4 2020 Feb 12, 2021	SELL	$207.01 - $276.09 $311,343 - $415,239	-1,504 Reduced 3.45%	42,029 $9.93 Million
Q3 2020 Oct 30, 2020	SELL	$255.65 - $303.1 $1.3 Million - $1.54 Million	-5,090 Reduced 10.47%	43,533 $11.8 Million
Q2 2020 Aug 12, 2020	SELL	$225.48 - $295.8 $29,537 - $38,749	-131 Reduced 0.27%	48,623 $14.1 Million
Q1 2020 May 13, 2020	BUY	$199.77 - $247.81 $946,310 - $1.17 Million	4,737 Added 10.76%	48,754 $11.6 Million
Q4 2019 Feb 12, 2020	BUY	$166.71 - $223.91 $2.25 Million - $3.02 Million	13,505 Added 44.26%	44,017 $9.64 Million
Q3 2019 Nov 13, 2019	SELL	$166.23 - $187.09 $2.19 Million - $2.46 Million	-13,149 Reduced 30.12%	30,512 $5.17 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $733,995 - $848,859	4,459 Added 11.37%	43,661 $8.01 Million
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $739,077 - $878,875	4,514 Added 13.01%	39,202 $7.21 Million
Q4 2018 Feb 13, 2019	BUY	$151.91 - $192.21 $3.11 Million - $3.93 Million	20,469 Added 143.96%	34,688 $5.75 Million
Q3 2018 Nov 13, 2018	BUY	$167.73 - $192.74 $1.3 Million - $1.5 Million	7,780 Added 120.83%	14,219 $2.74 Million
Q2 2018 Aug 13, 2018	BUY	$145.72 - $169.96 $384,263 - $448,184	2,637 Added 69.36%	6,439 $1.1 Million
Q1 2018 May 14, 2018	BUY	$151.6 - $177.13 $295,013 - $344,694	1,946 Added 104.85%	3,802 $619,000
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $49,283 - $55,842	-359 Reduced 16.21%	1,856 $278,000
Q3 2017 Nov 14, 2017	SELL	$148.13 - $162.24 $37,921 - $41,533	-256 Reduced 10.36%	2,215 $336,000
Q2 2017 Aug 14, 2017	BUY	N/A	2,471	2,471 $319,000

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bokf, Na, based on Form 13F filings with the SEC.

News

Stay updated on Bokf, Na with notifications on news.

Account